Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer

PLoS ONE(2021)10.1371/journal.pone.0248380Source: DataRank Database

Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer is a research paper published in PLoS ONE (2021). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

gen doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)OA: goldTopics (76)IDs (PubMed, PMC)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Vineeta Bajaj,Yanan Guo,Izabela A. Malinowska,Jianming Zhang ORCID,David J. Kwiatkowski ORCID

Live enrichment

PubMed:33891611 PMC:PMC8064564

National Cancer Institute

Grant: 1P01CA120964

NCI NIH HHS

Grant: P01 CA120964

National Institutes of Health

Grant: 2P01CA120964-06A1

Molecular wiring and therapeutic targeting of the TSC-Rheb signaling network

goldLicense: cc-by

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0248380&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0248380

repositoryhttps://doaj.org/article/909a6fb01eae496fab917357e7b74006

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8064564

Europe_PMChttps://europepmc.org/articles/PMC8064564

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciencesAnimalsBenzoxazolesCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHSP90 Heat-Shock ProteinsHumansMaleMechanistic Target of Rapamycin Complex 1MiceMice, Inbred C57BLMice, NudeMutationNaphthyridinesNeoplasmsProtein Kinase InhibitorsPyrimidinesSignal TransductionTOR Serine-Threonine KinasesTuberous SclerosisTuberous Sclerosis Complex 1 ProteinTuberous Sclerosis Complex 2 ProteinXenograft Model Antitumor AssaysAdenine

MeSH Terms

Cell Line, TumorAnimalsMice, Inbred C57BLHumansMiceMice, NudeNeoplasmsTuberous SclerosisPyrimidinesBenzoxazolesNaphthyridinesAdenineProtein Kinase InhibitorsDrug Screening Assays, AntitumorXenograft Model Antitumor AssaysSignal TransductionCell ProliferationMutationMaleHSP90 Heat-Shock ProteinsTOR Serine-Threonine KinasesMechanistic Target of Rapamycin Complex 1Tuberous Sclerosis Complex 1 ProteinTuberous Sclerosis Complex 2 Protein

Keywords

MaleScienceMice, NudeMechanistic Target of Rapamycin Complex 1MiceTuberous SclerosisCell Line, TumorNeoplasmsAnimalsHumansHSP90 Heat-Shock ProteinsNaphthyridinesProtein Kinase InhibitorsCell ProliferationBenzoxazolesTOR Serine-Threonine KinasesQRMice, Inbred C57BLPyrimidinesMutationMedicineDrug Screening Assays, AntitumorResearch ArticleSignal Transduction

Sustainable Development Goals

SDG 3: 3. Good health

Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer

FAIR Checklist

Authors (6)

Funding (3 grants)

Open Access

Topics

Annotations (Europe PMC)